Your shopping cart is currently empty

1-Phenylbiguanide HCl, as 5-HT3 receptor agonists(3–100 μM, pEC50 5.05±0.06), acutely increased XII (hypoglossal) burst frequency and regularity, and decreased bursts/episode . 1-Phenylbiguanide HCl produced a dose-related (10-500 microM) increase in the release of dopamine (280-2000%). When nomifensine (5 microM) was included in the Ringer solution, the effect of 1-Phenylbiguanide HCl on the release of dopamine was ameliorated or inhibited.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 200 mg | $29 | - | In Stock |
| Description | 1-Phenylbiguanide HCl, as 5-HT3 receptor agonists(3–100 μM, pEC50 5.05±0.06), acutely increased XII (hypoglossal) burst frequency and regularity, and decreased bursts/episode . 1-Phenylbiguanide HCl produced a dose-related (10-500 microM) increase in the release of dopamine (280-2000%). When nomifensine (5 microM) was included in the Ringer solution, the effect of 1-Phenylbiguanide HCl on the release of dopamine was ameliorated or inhibited. |
| Targets&IC50 | 5-HT3 receptor:3 μM (EC50) |
| Synonyms | Phenylbiguanide hydrochloride |
| Molecular Weight | 213.67 |
| Formula | C8H12ClN5 |
| Cas No. | 55-57-2 |
| Smiles | Cl.NC(N)=NC(=N)NC1=CC=CC=C1 |
| Relative Density. | 1.33g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.